Visicol is a drug owned by Salix Pharmaceuticals Inc. It is protected by 1 US drug patent filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be May 18, 2013. Details of Visicol's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US5616346 | Non-aqueous colonic purgative formulations |
May, 2013
(11 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Visicol is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Visicol's family patents as well as insights into ongoing legal events on those patents.
Visicol's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Visicol's generic launch date based on the expiry of its last outstanding patent is estimated to be May 18, 2013 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Visicol Generic API suppliers:
Sodium Phosphate, Dibasic, Anhydrous; Sodium Phosphate, Monobasic, Monohydrate is the generic name for the brand Visicol. 1 company has already filed for the generic of Visicol. Check out the entire list of companies who have already received approval for Visicol's generic
Alternative Brands for Visicol
Visicol which is used for bowel cleansing before colonoscopy., has several other brand drugs using the same active ingredient (Sodium Phosphate, Dibasic, Anhydrous; Sodium Phosphate, Monobasic, Monohydrate). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Salix Pharms |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Sodium Phosphate, Dibasic, Anhydrous; Sodium Phosphate, Monobasic, Monohydrate, Visicol's active ingredient. Check the complete list of approved generic manufacturers for Visicol
About Visicol
Visicol is a drug owned by Salix Pharmaceuticals Inc. It is used for bowel cleansing before colonoscopy. Visicol uses Sodium Phosphate, Dibasic, Anhydrous; Sodium Phosphate, Monobasic, Monohydrate as an active ingredient. Visicol was launched by Salix Pharms in 2000.
Approval Date:
Visicol was approved by FDA for market use on 21 September, 2000.
Active Ingredient:
Visicol uses Sodium Phosphate, Dibasic, Anhydrous; Sodium Phosphate, Monobasic, Monohydrate as the active ingredient. Check out other Drugs and Companies using Sodium Phosphate, Dibasic, Anhydrous; Sodium Phosphate, Monobasic, Monohydrate ingredient
Treatment:
Visicol is used for bowel cleansing before colonoscopy.
Dosage:
Visicol is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.398GM;1.102GM | TABLET | Discontinued | ORAL |